Veru Inc.

For big pharma companies who want a major stake in the ballooning obesity market, opportunities to license in a mid-stage asset are dwindling. Roche claimed one of the top unlicensed candidates on 12

Although GLP-1 agonists for obesity have made a significant difference for patients and brought in a financial windfall for their manufacturers, there remains a lingering problem of the drugs reducing

Another company joined the burgeoning obesity therapy space on 28 January, as Versant Ventures-backed Helicore Biopharma unveiled a $65m series A financing and initial plans to take a first-in-class

Veru Inc. started out focused mainly on cancer supportive therapy, but now thinks it has identified a new direction for its lead candidate, the selective androgen receptor modulator (SARM) enobosarm,